Outcome in small-vessel systemic vasculitis. ‌ Luqmani, R, Flossmann, O

Clinical and biological assessment in systemic necrotizing vasculitides. ‌ Mukhtyar, C, Flossmann, O, Luqmani, R

Eular recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis ‌ Hellmich, B, Flossmann, O, Luqmani, R

Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis? ‌ Flossmann, O, Jones, R, Jayne, DR, Luqmani, R

Current evidence of factors influencing remission, relapse, renal failure and mortality in patients with systemic vasculitis. A systematic review for the EULAR systemic vasculitis... ‌ Mukhtyar, C, Flossmann, O, Hellmich, B, Luqmani, R, EUVAS

Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis. ‌ Mukhtyar, C, Hellmich, B, Jayne, D, Flossmann, O, Luqmani, R

EULAR recommendations for conducting clinical studies and/or clinical trials in ANCA-associated vasculitis ‌ Luqmani, R, Flossmann, O, Jayne, D, Hellmich, B, Taskforce, E

Long-term follow up of EUVAS studies ‌ Flossmann, O, Harper, L, Jayne, D, Luqmani, R, Westman, K

The role of biologic therapies in the management of systemic vasculitis. ‌ Chan, A, Flossmann, O, Mukhtyar, C, Jayne, DR, Luqmani, R

Factors influencing remission, relapse, renal failure and mortality in patients with systemic vasculitis ‌ Luqmani, R, Mukhtyar, C, Flossmann, O, Hellmich, B, Jayne, D

Cardiovascular outcomes in ANCA associated vasculitis ‌ Mukhtyar, C, Flossmann, O, Brown, D, Westman, K, Jayne, D, Luqmani, R

Heavy chain deposition disease presenting with raised anti-GBM antibody levels; a case report ‌ Turner, M, Crawford, A, Winterbottom, C, Flossmann, O, Alchi, B, Soares, M, Bhandary, U

Development of comprehensive disease assessment in systemic vasculitis. ‌ Flossmann, O, Bacon, P, de Groot, K, Jayne, D, Rasmussen, N, Seo, P, Westman, K, Luqmani, R

Development of comprehensive disease assessment in systemic vasculitis. ‌ Flossmann, O, Bacon, P, de Groot, K, Jayne, D, Rasmussen, N, Seo, P, Westman, K, Luqmani, R

Long-term damage to the ENT system in Wegener's granulomatosis. ‌ Martinez Del Pero, M, Walsh, M, Luqmani, R, Flossmann, O, Mukhtyar, C, Jani, P, Rasmussen, N, Jayne, D

Prospective clinical trial of Gusperimus (deoxyspergualin) in refractory Wegener's granulomatosis ‌ Flossmann, O, Baslund, B, Bruchfeld, A, Cohen Tervaert, J, Heinzel, P, Hellmich, B, Luqmani, R, Tesar, V, Jayne, D

Treatment related damage in the ANCA-associated vasculitides: An analysis of cohorts from the European Vasculitis Study Group (EUVAS) therapeutic trials ‌ Robson, J, Doll, H, Flossmann, O, Ravi, S, Lorraine, H, Peter, H, David, J, Chetan, M, Kerstin, W, Raashid, L

Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials. ‌ Robson, J, Doll, H, Suppiah, R, Flossmann, O, Harper, L, Höglund, P, Jayne, D, Mahr, A, Westman, K, Luqmani, R

Glucocorticoid Treatment and Damage In The Antineutrophil- Cytoplasm Antibody Associated Vasculitides ‌ Robson, J, Doll, H, Suppiah, R, Flossmann, O, Harper, L, Hoglund, P, Jayne, D, Mahr, A, Westman, K, Luqmani, R

Damage in the ANCA-associated vasculitides: Long-term data from the European Vasculitis Study Group (EUVAS) therapeutic trials ‌ Robson, J, Doll, H, Suppiah, R, Flossmann, O, Harper, L, Höglund, P, Jayne, D, Mahr, A, Westman, K, Luqmani, R